You are here

Portfolio Manager

2002 - 2007

  • Medicinal Chemist, BioFocus Discovery

2007 - 2010

  • Project Leader, Drug Discovery Unit

2010 -

  • Portfolio Manager, Drug Discovery Unit

Andrew coordinates and manages the Innovative Targets Portfolio including pipeline development, new project entry, project planning and resourcing, project and program management, and coordination of the Scientific Advisory Board. A Prince2 qualified project manager, Andrew has overseen the growth of the ITP from a handful of projects to an active portfolio of circa 20 projects at any given time.

Andrew is a medicinal chemist with industrial experience and capabilities in drug discovery from the validation of hits from assays, to the development of leads with in vivo efficacy. At BioFocus, Andrew worked on a number of protein kinase and ion channel drug discovery projects and designed cutting edge product lines, such as DGF-out kinase inhibitors, ion channel modulators and fragment libraries. In particular, he led the development of the first DGF-Out kinase library which sold out within 3 days based solely on its pre-production design.

Andrew joined the DDU as a project leader and successfully progressed projects through hit to lead and in to lead optimisation programs as potential treatments for nagana and leishmaniasis. Since becoming Portfolio Manager for the Innovative Targets Portfolio, Andrew has initiated over 20 promising drug discovery projects addressing a range of therapeutic indications, across a number of target classes (protein-protein interactions, kinases, ion channels, DUBs and other proteases and E3 ligases). By flexibly structuring projects to answer project specific questions and rapidly closing projects which reach their natural conclusions, the ITP has a demonstrated ability to progress higher risk – higher reward projects as well as more conventional drug discovery projects. Under Andrew’s management, early success in the ITP led to 2 partnerships with GSK through their DPAc Scheme.

Andrew continues to develop the ITP with a strong pipeline of future opportunities. This includes building relationships with leading academics and industrial collaborators as well as clinical experts and opinion leaders.